NanoViricides, Inc. (NYSE American: NNVC) announced that the Democratic Republic of Congo’s regulatory agency, ACOREP, has approved the start of a Phase II clinical trial evaluating NV-387 for the treatment of MPox caused by hMPXV infection. The trial will assess safety and effectiveness, pending final document submissions. “This is an important milestone in regulatory development of NV-387,” said Anil R. Diwan, PhD, President and Executive Chairman.
NV-387 is designed to mimic human cells to trap and destroy viruses and has shown potential as a broad-spectrum antiviral targeting up to 95% of human pathogenic viruses. The Company believes the drug could represent a major breakthrough in antiviral therapy, similar to how antibiotics transformed bacterial disease treatment. The full press release can be accessed at https://ibn.fm/WdFf1.
This approval is crucial as MPox continues to pose a public health threat, particularly in regions like the DRC. The Phase II trial will provide data on NV-387’s safety and efficacy in humans, moving the drug closer to potential approval. If successful, NV-387 could offer a new treatment option for MPox and other viral infections, addressing a significant unmet medical need.
The implications of this announcement extend beyond MPox. NV-387 is being developed as a broad-spectrum antiviral drug for multiple indications, including RSV, COVID, Long COVID, Influenza, and other respiratory viral infections. The Company’s lead drug candidate represents a novel approach to antiviral therapy, which could revolutionize treatment paradigms if proven effective in clinical trials.
NanoViricides’ platform technology is based on nanomedicine from TheraCour Pharma, Inc., and the Company holds exclusive licenses for several antiviral drugs. The Company is also developing drugs against a range of viral diseases, including herpes, influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola. The latest news and updates relating to NNVC are available in the company’s newsroom at https://ibn.fm/NNVC.
As with any drug development, there are risks. The path to approval is lengthy and requires substantial capital. There can be no assurance that NV-387 will show sufficient effectiveness and safety in human trials. However, the regulatory approval in the DRC marks a critical step forward, bringing the potential of a broad-spectrum antiviral closer to reality.
